Company ProfilePremium

Hydrix Limited

Company Profile Analysis

Ticker: HYD.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Hydrix Limited - Company showcase

Year Founded & Workforce

1993

50 Employees

Hydrix Limited logo

Hydrix Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Hydrix Limited Overview

Hydrix Limited is an Australian micro-cap technology company whose core asset is Hydrix Services, a Melbourne-based multidisciplinary engineering consultancy that designs and develops safety-critical products — principally Class III active implantable cardiovascular devices, surgical robotics and, increasingly, sovereign defence systems — for international medtech start-ups and Australian defence primes. Around three-quarters of FY2026 revenue came from outside Australia. Around this fee-for-service engine the group has layered three option-value businesses: Hydrix Medical (distribution of the Implicity AI remote cardiac monitoring platform in Australia and Southeast Asia), Hydrix Ventures (equity stakes in former clients such as Gyder Surgical and Wavewise), and, since May 2026, Hydrix Defence, a vehicle to acquire, licence or develop proprietary defence intellectual property. The company has never been profitable at group level, carries negative shareholders' equity, depends on director-provided debt and equity, and in 2026 recapitalised at A$0.005 per share. It is best characterised as a distressed-but-recapitalised engineering services platform pivoting toward technology ownership.


Company's own description (paraphrased from the FY2026 Appendix 4E Operational and Financial Review). Hydrix states its purpose as enhancing people's health, safety and well-being by leveraging its product innovation capability across four business segments operated through four wholly owned subsidiaries. During FY2026 its principal activities were product design and development consulting for clients in the medical and defence technology sectors, marketing remote cardiac monitoring technology, and managing a portfolio of venture investments in early-stage medtech companies. The listed parent, Hydrix Limited, is not itself a revenue-generating unit. The FY2026 Chairman's Letter recasts the group as an Australian technology company spanning medical technology, defence, industrial and mining, combining engineering, technology investment, IP development and commercialisation.

The four segments (FY2026 definitions):

  1. Hydrix Services — end-to-end multidisciplinary product design and development consulting across medtech, cardiac health, defence and industrial sectors: safety-critical control systems engineering, software, electronics, mechanical, human factors and industrial design; services span applied research, engineering design, prototyping, manufacturer management and certification process management. This segment produced substantially all group revenue in FY2024–FY2026.

  2. Hydrix Defence (established May 2026) — evaluating investments, acquisitions and IP licensing to own technologies delivering higher-value, longer-duration revenue; areas of interest include embedded intelligence, autonomy-enabling technologies, advanced sensing, electronic warfare, navigation and counter-UAS, aligned to Australian Defence Force (ADF) capability needs, border security and critical infrastructure protection.

  3. Hydrix Medical — distributes Implicity's cloud-based, AI-driven remote cardiac patient monitoring and data management platform under licence across Australia and Southeast Asia (sales focus: Australia, Singapore, New Zealand). Previously also distributed the Avertix Medical (formerly Angel Medical Systems) Guardian implantable heart-attack warning system, whose distribution-rights asset was impaired to nil in FY2024.

  4. Hydrix Ventures — selectively invests in Hydrix Services medtech clients to generate equity capital gains; current portfolio: Gyder Surgical Pty Ltd (orthopaedic hip-replacement navigation tool) and Wavewise Pty Ltd (non-invasive brain trauma injury monitoring device).

Business and revenue model. Revenue is overwhelmingly professional services (fee-for-service, time-and-materials and milestone-based engineering contracts) recognised as "revenue from contracts with customers". There is a small product element: Hydrix has sold units of its proprietary LUDO mechanical heart controller (five units sold in FY2024) to clients developing total artificial heart and assistive heart technologies, which the company positions as a lead-generator for subsequent fee-for-service work. Hydrix Medical targets software-as-a-service recurring revenue (pipeline cited at >A$2.5m ARR in FY2024, >A$2.0m in H1 FY2025 and >A$1.5m in H1 FY2026), but had not reported material recognised revenue from it in the periods reviewed. Hydrix Ventures generates no operating revenue; its results flow through fair-value gains and losses on financial assets. No licensing royalties are disclosed.

Value-chain position. Hydrix sits in the outsourced product development (OPD) / engineering-services layer between a client's concept and contract manufacturing. It does not manufacture at scale, but offers "manufacturer management" and regulatory/certification support. In medtech it acts as design-and-development partner for start-ups that lack in-house engineering depth, particularly for high-risk implantables; in defence it acts as an engineering subcontractor to primes and SMEs (e.g., NIOA Group, Phasor Innovation).

Customer types and end-markets.

Independent characterisation. Hydrix is, in substance, a ~50-person specialist engineering consultancy with a niche reputation in Class III cardiovascular implantables, bolted to a listed shell with ~A$116 million of accumulated losses (the bulk inherited from the Panorama Synergy era and the post-2017 investment phase). Its revenue base (~A$10 million) has been flat-to-declining for three years, its client base is concentrated in venture-funded start-ups whose funding volatility directly hits Hydrix's utilisation (as the SynCardia pause in Q4 FY2026 showed), and its balance sheet has relied on director loans and letters of comfort. The 2026 strategic pivot toward defence IP ownership is coherent with Australian sovereign-capability spending trends but is, as yet, unfunded beyond the 2026 entitlement offer and unproven.

Strategy

Stated strategy (themes from FY2026 Chairman's Letter and Appendix 4E, paraphrased).

  1. From services to technology ownership. Leverage the high-value engineering services capability to pursue technology and IP ownership in high-priority Australian sovereign capability domains, aiming for larger, recurring revenue streams; the stated objective is to combine world-class engineering services with valuable proprietary technology and IP.

  2. International medtech growth. Pursue larger international medtech programs (core growth strategy), particularly cardiovascular and safety-critical devices and surgical robotics.

  3. Sovereign defence growth. Use Hydrix Services' decade-plus of defence program experience and the new Hydrix Defence subsidiary to address ADF capability needs (sensing, autonomy, EW, navigation, counter-UAS), border security and critical infrastructure.

  4. Disciplined Medical commercialisation. Progress Implicity commercialisation while matching investment to customer and reimbursement milestones.

  5. Capital preservation in Ventures. Continue supporting portfolio companies but deploy no new venture capital (none deployed in FY2026).

  6. Simplified capital structure. Use the 2026 equity raise and debt conversion to reduce cash obligations and enable growth.

Strategic initiatives register (last 24 months).

ESG/sustainability commitments: none disclosed. Medium-term financial targets: none disclosed. The only forward-looking quantitative markers are pipeline figures: estimated future program value in excess of A$37m across more than 15 active client programs (FY2026), down from ~A$40m cited repeatedly through FY2024–H1 FY2026; ~A$4.0m of contract sales signed since 30 June 2026 (to 28 Aug 2026); and A$6.5m of new contracts referenced in the June 2026 quarterly as supporting the FY2027 revenue outlook.

Products & Services

Hydrix Services — capabilities

OfferingDescription / capabilityTarget customerPricing modelSource
Safety-critical control systems engineeringDesign of control systems where failure risks life, incl. Class III active implantablesCardiovascular medtech developersFee-for-service, milestoneAppendix 4E FY2026; FY2024 report
Embedded software engineeringSafety-critical software, firmware (e.g., Remedy Robotics N1)Medtech robotics, defenceFee-for-serviceChairman's Letter FY2026
Electronics engineeringEmbedded electronics, sensingMedtech, defenceFee-for-serviceChairman's Letter FY2026
Mechanical engineering & industrial designProduct mechanical design, enclosures, mechanismsAll sectorsFee-for-serviceAppendix 4E FY2026
Human factors & UX engineeringUsability engineering for regulated devicesMedtechFee-for-serviceMorningstar profile; Appendix 4E
Regulatory, clinical, reimbursement & quality systems consultingCertification process management, regulatory submissions supportMedtech start-upsFee-for-serviceMorningstar profile; Appendix 4E
Applied research → prototyping → manufacturer managementFull lifecycle from research to transfer-to-manufactureAllFee-for-serviceAppendix 4E FY2026
Systems engineering for defenceCounter-UAS payload subsystems, quantum navigation supportDefence primes/SMEsContractChairman's Letter FY2026

Proprietary products

ProductDescriptionLaunch / statusPricingSource
LUDO mechanical heart controllerHydrix-developed and owned controller technology used by clients developing total replacement and assistive heart devices5 units sold in FY2024—Appendix 4E FY2024

Named client programs / products developed by Hydrix Services (illustrative portfolio)

Client / productDescriptionYear referencedSource
SynCardia Systems (USA) — Emperor Total Artificial HeartA$2.5m development contract for next-generation TAH; paused Q4 FY2026 pending client fundingFY20264C Jan 2026; Appendix 4E FY2026
Remedy Robotics (USA) — N1 remote endovascular intervention robotA$3.4m contract for safety-critical software and embedded electronicsFY2026Chairman's Letter FY2026
Quantanosis — robotic stroke therapy platformNext-generation robotic stroke therapy development supportFY2026Chairman's Letter FY2026
NIOA Group (Australia) — counter-UAS payload subsystemA$1.2m defence development contractFY2026Chairman's Letter FY2026
Phasor Innovation — quantum sensing & navigationNavigation for GPS-denied undersea, maritime, airborne and land applicationsJun 2026ASX 4 Jun 2026; Chairman's Letter
Gyder Surgical — GYDER Hip SystemOrthopaedic hip-replacement navigation tool; FDA 510(k) Feb 2025; US commercialisation began 20262025–20264C Apr 2025; Appendix 4E FY2026
Wavewise — non-invasive brain monitorContinuous monitor to detect brain hypoxia / traumaFY2023–FY2026Appendix 4E FY2024, FY2026
Unnamed USA client — remotely operated catheter-guidance robotEndovascular interventionsFY2024Appendix 4E FY2024
Unnamed European client — Left Ventricular Assist DeviceCardiacFY2024Appendix 4E FY2024
Unnamed European client — Total Artificial HeartCardiacFY2024Appendix 4E FY2024
Unnamed European client — wound therapy deviceMedtechFY2024Appendix 4E FY2024
Memphasys — Felix SystemSperm-separation device; positive results reportedFY2023Appendix 4D Feb 2023
Chemring — portable EM blocking deviceDefence/security sensingHistoricalMorningstar profile
Universal Biosensors — coagulation analyserDiagnosticsHistoricalMorningstar profile
Micro-X — mobile X-rayImagingHistoricalMorningstar profile
Angel Medical Systems / Avertix — GuardianImplantable heart-attack warning system (Hydrix also built devices)2020 onwardBiotech Daily 2020

The five largest FY2024 clients (the unnamed USA, Europe and Australia programs above) delivered A$7.25m of FY2024 revenue (~68% of revenue, derived) — Appendix 4E FY2024.

Hydrix Medical

ProductDescriptionTerritoryStatusPricingSource
Implicity remote cardiac monitoring platformCloud-based, AI-driven remote monitoring and data management for cardiac implantable device patientsAustralia, Southeast Asia (sales focus Australia, Singapore, NZ)Licensed May 2023; pipeline >A$1.5m ARR (H1 FY2026); long, reimbursement-dependent sales cyclesSaaS (rates not disclosed)Appendix 4E FY2024, FY2026; Appendix 4D Feb 2026
Avertix Medical GuardianImplanted real-time heart-attack warning systemSingapore, Malaysia, Thailand approvals; Australia (TGA application withdrawn 2023)8 sales/implants in Singapore to FY2024; distribution rights impaired to nil at 30 Jun 2024—Appendix 4E FY2024
Second AI cardiovascular product (FY2023 agreement)One of two AI cardiovascular distribution agreements announced FY2023 (other than Implicity)—Not named in sources reviewed; no subsequent disclosure—FY2023 results announcement

Hydrix Ventures

InvesteeDescriptionStatusSource
Gyder Surgical Pty LtdGYDER Hip System; FDA 510(k) Feb 2025; US commercialisation commenced 2026; recent capital raise at lower valuation → A$2.3m mark-downHeldAppendix 4E FY2026
Wavewise Pty LtdNon-invasive brain trauma monitoringHeldAppendix 4E FY2026
Avertix Medical (formerly Angel Medical Systems)Guardian owner; Nasdaq IPO filing 2023; written down to A$0.14m Aug 2024No longer listed among portfolio companies in FY2026 (portfolio now "two" companies, versus three in FY2025)Appendix 4E FY2024, FY2025, FY2026

Hydrix Defence

Focus areaDescriptionStatusSource
Embedded intelligence & autonomyTechnologies for field-ready sovereign assets in contested environmentsEvaluating acquisitions/licencesAppendix 4E FY2026
Advanced sensing, electronic warfare, navigation, counter-UASAligned to ADF prioritiesPipeline; no acquisition announced as of the dossier dateChairman's Letter FY2026
European defence market engagementBusiness development activityAnnounced 17 Jun 2026ASX announcement

Financial Narrative

Income statement

Sources and notes: FY2025–FY2026 line items from the FY2026 Appendix 4E consolidated statement of profit or loss (unaudited FY2026). FY2022–FY2024 revenue and net loss from aggregator series (Stoxray/TipRanks) cross-checked against company statements: FY2024 revenue A$10.6m and loss A$9.6m (Appendix 4E FY2024 — includes A$4.2m non-cash/non-recurring items incl. A$2.5m Guardian impairment and A$1.75m Avertix write-down); FY2023 revenue is reported by the company as A$13.3m (FY2023 results announcement) versus A$13.16m on aggregators — the difference likely reflects inclusion of other income; FY2023's unusually small net loss (A$0.40m) is per aggregator data and was not reconciled to the audited FY2023 statements in this research. FY2021 net loss was A$9.78m (Appendix 4E FY2021). EPS FY2023/FY2024 per Simply Wall St (7 Oct 2024); FY2025/FY2026 per Appendix 4E FY2026 (the 4E column layout was cross-checked against weighted share counts). Derived EBITDA = loss before tax + finance costs + D&A − interest income. Gross profit is not reported (Hydrix presents expenses by nature, not cost of sales).

Margins and growth

Revenue CAGR FY2022–FY2026 (derived): −1.4% per annum (A$10.33m → A$9.74m). FY2022 growth derived from aggregator FY2021 revenue of A$7.45m.

Commentary. The five-year picture is one of a services business that briefly scaled (FY2023 peak of ~A$13.2–13.3m, driven by 34% fee-revenue growth and 34% international growth) and then contracted as venture-funded clients delayed or cancelled programs in the tighter post-2022 funding environment. FY2024 revenue fell 19% on client funding challenges, budget constraints, delayed commencements and program completions (Appendix 4E FY2024). Management responded with cost reductions (A$1.7m annualised in FY2024; A$3.2m savings cited in FY2025), which drove the improvement in the FY2025 loss before tax from A$9.6m to a statutory A$3.65m (the FY2025 results summary cited A$2.9m on an adjusted basis). FY2026 regressed: revenue slipped a further 3.5% due to client-funding-driven delivery slippage, chiefly the Q4 pause in SynCardia's Emperor program; the statutory loss nearly doubled to A$6.72m, but A$2.75m of this was non-cash fair-value loss (A$2.3m attributable to the Gyder mark-down). The adjusted loss widened modestly to A$3.96m from A$3.19m. The structural problem is visible in the cost base: employee costs absorb ~89% of revenue, leaving no room for overhead, finance costs (A$1.2m, ~12.5% of revenue, reflecting 8–12% related-party loans), or D&A. Breakeven requires either ~A$13–14m of revenue at current cost or materially higher utilisation and pricing.

Balance sheet

Sources: Appendix 4E FY2026 balance sheet and statement of changes in equity (FY2024 closing equity, issued capital and accumulated losses taken from the 1 July 2024 opening balances); FY2024 cash from the FY2025 cash flow statement opening balance; Ventures values FY2023–FY2024 from Appendix 4E FY2024 (the FY2023 results announcement separately cited Ventures NTA of A$4.9m — a discrepancy with the A$5.1m figure quoted in FY2024, likely reflecting different measurement dates or bases).

Commentary. Hydrix has had negative equity since at least FY2024, deepening to −A$8.15m at 30 June 2026 despite the A$5.3m equity raise (net of costs, including A$3.45m allocated to option reserves) because of the A$6.72m loss and the collapse of the Ventures portfolio value. Borrowings (A$7.25m, all current at 30 June 2026) consist mainly of loans and convertible notes owed to directors (A$5.9m) plus A$0.2m external convertible notes. After balance date, up to A$5.1m of debt-conversion commitments were secured; the company states that if no further shortfall capital is raised, A$3.9m will convert, leaving pro forma residual debt of A$2.2m (excluding accrued interest). Pro forma, this would improve equity by A$3.9m but equity would remain negative (derived: roughly −A$4.3m) absent further raises. The A$1.0m trade debtors facility at Hydrix Services was extinguished from the raise proceeds.

Cash flow

Sources: Appendix 4E FY2026 cash flow statement (FY2025, FY2026); Appendix 4E FY2024 (FY2024 OCF A$1.9m used and FY2023 A$2.7m used; FY2024 receipts A$12.3m). FY2022 OCF from aggregator series (Stoxray). Note: Stoxray reports FY2023 OCF as −A$3.12m versus the company's −A$2.7m; the company figure is used and the discrepancy flagged.

FY2026 quarterly cash profile (AUD millions)

Sources: Appendix 4C reports (28 Oct 2025; 30 Jan 2026, amended 2 Feb 2026; 30 Jul 2026). Q3 operating cash flow is derived as the full-year figure less the other three quarters. Q1 and Q3 revenue were not captured from primary sources.

Commentary. Operating cash burn had narrowed impressively from ~A$6.6m (FY2022) to ~A$0.5m (FY2025), demonstrating the cost-out program's effectiveness, before re-widening to A$1.9m in FY2026, almost entirely in Q4 (A$1.63m outflow), when SynCardia work stopped and a receivable was delayed while staff costs (A$2.39m in the quarter) continued. The business is extremely sensitive to single-client timing. Capex is negligible (~A$50k a year), consistent with an asset-light consultancy. Funding has come entirely from directors' loans, letters of comfort (A$2.0m in Aug 2024, A$2.5m in total by Oct 2025, A$2.2m cited Feb 2026) and, in FY2026, the entitlement offer.

Ratios

Notes: ROE and debt/equity are not meaningful because equity is negative; ROIC and net debt/EBITDA are not meaningful because EBIT and EBITDA are negative (cells left blank). Cash conversion cycle: not publicly disclosed (receivables of A$1.50m against revenue of A$9.74m imply roughly 56 days of sales outstanding at FY2026 year end, derived, but payables-days data is incomplete). Revenue per employee FY2025 matches the TipRanks figure of A$183.5k.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segments Reported by Period

PeriodSegments reportedChange

FY2019–FY2023

Hydrix Services; Hydrix Medical; Hydrix Ventures (Ventures from 2019; Medical from 2020)

Medical added after Guardian rights acquisition (2020)

FY2024–FY2025

Services; Medical; Ventures (some aggregators describe "two segments", Services and Medical, treating Ventures as investment holdings)

Guardian impaired to nil; Implicity becomes main Medical product

FY2026

Services; Defence; Medical; Ventures

Hydrix Defence added May 2026 (minimal costs in FY2026)

Revenue by Segment

SegmentFY2024FY2025FY2026

Hydrix Services revenue (AUD Mn)

10.6110.099.74

Hydrix Medical revenue (AUD Mn)

000

Hydrix Ventures operating revenue (AUD Mn)

000

Hydrix Defence revenue (AUD Mn)

——0

Group revenue from contracts with customers (AUD Mn)

10.6110.099.74

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Services % of group revenue

100100100

Services revenue YoY growth (%)

-19-4.9-3.5

Services signed contract value (AUD Mn)

—9.911.7

Segment profit metric (AUD Mn)

Segment profit metric (AUD Mn)FY2024FY2025FY2026

Hydrix Services cash operating profit, H1 only (AUD Mn)

—0.42—

Hydrix Ventures fair-value movement (AUD Mn)

-1.750.15-2.75

Hydrix Ventures portfolio book/NTA value at year end (AUD Mn)

3.353.170.42

Hydrix Limited (parent) operating cost increase (AUD Mn)

——0.1

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from contracts with customers (AUD Mn)

10.3313.1610.6110.099.74

Other income incl. interest (AUD Mn)

———0.180.11

Total income (AUD Mn)

———10.279.86

Employee benefits expense (AUD Mn)

———8.938.65

Project material expenses (AUD Mn)

———0.560.86

Other expenses (AUD Mn)

———1.762.00

Depreciation & amortisation (AUD Mn)

———0.760.53

Finance costs (AUD Mn)

———1.051.22

Fair-value loss on financial instruments (AUD Mn)

———0.462.75

Total expenses (AUD Mn)

———13.9316.57

Loss before income tax (AUD Mn)

———-3.65-6.72

Net loss after tax (AUD Mn)

-5.55-0.40-9.56-3.65-6.72

Adjusted loss excl. non-cash FV losses (AUD Mn)

———-3.19-3.96

EBITDA, derived (AUD Mn)

———-1.86-5.00

EBITDA excl. FV losses, derived (AUD Mn)

———-1.39-2.25

Basic & diluted EPS (AUD cents)

—-0.2-3.8-1.38-1.86

Dividends per share (AUD cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

38.727.4-19.2-4.9-3.5

Revenue less project materials margin, derived proxy (%)

———94.491.2

Operating (EBIT) margin, derived (%)

———-26.0-56.8

EBITDA margin, derived (%)

———-18.4-51.3

EBITDA margin excl. FV losses, derived (%)

———-13.8-23.1

Net margin (%)

-53.7-3.0-90.1-36.2-69.0

Employee costs as % of revenue (%)

———88.488.8

Balance Sheet and Per-Share Data

MetricFY2023FY2024FY2025FY2026

Total assets (AUD Mn)

——7.626.09

Cash & cash equivalents (AUD Mn)

—0.910.302.96

Trade & other receivables (AUD Mn)

——1.731.50

Financial assets at FVTPL — Ventures (AUD Mn)

5.13.353.170.42

Intangible assets (AUD Mn)

——0.180

Goodwill (AUD Mn)

——00

Right-of-use assets (AUD Mn)

——0.960.59

Current borrowings (AUD Mn)

——6.087.25

Non-current borrowings (AUD Mn)

——1.000

Total borrowings (AUD Mn)

——7.087.25

Lease liabilities, total (AUD Mn)

——1.581.09

Net debt excl. leases, derived (AUD Mn)

——6.794.29

Net debt incl. leases, derived (AUD Mn)

——8.365.39

Total liabilities (AUD Mn)

——14.3914.24

Total equity (AUD Mn)

—-3.36-6.77-8.15

Issued capital (AUD Mn)

—102.13102.41104.28

Accumulated losses (AUD Mn)

—-105.84-109.24-115.88

Working capital, derived (AUD Mn)

——-9.27-8.57

NTA per share (AUD cents)

——-2.55-0.56

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers incl. GST (AUD Mn)

——12.310.0811.02

Net operating cash flow (AUD Mn)

-6.58-2.7-1.89-0.53-1.91

Capex: PP&E + intangibles (AUD Mn)

———0.050.05

Free cash flow, derived (AUD Mn)

———-0.58-1.96

Proceeds from share issues (AUD Mn)

———05.22

Net borrowings (AUD Mn)

———1.050.52

Interest and finance costs paid (AUD Mn)

———0.440.60

Lease repayments (AUD Mn)

———0.680.48

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Cash Flow (Quarterly)

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026

Quarterly revenue (AUD Mn)

—2.3—2.2

Net operating cash flow (AUD Mn)

-0.280.05-0.05-1.63

Cash at quarter end (AUD Mn)

0.310.58—2.96

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

Return on assets, year-end assets, derived (%)

-48.0-110.4

Current ratio, derived (x)

0.220.36

Interest coverage, EBIT/finance costs (x)

-2.5-4.5

Asset turnover, year-end assets, derived (x)

1.321.60

Revenue per employee, derived (AUD K)

183195

Revenue by Region (%) and Revenue by Region

MetricFY2023FY2024FY2025FY2026

International share of revenue (%)

57736373

Australian share of revenue (%)

43273727

International revenue, derived (AUD Mn)

7.507.756.367.11

Australian revenue, derived (AUD Mn)

5.662.863.732.63

International revenue growth, derived (%)

—3.3-17.911.8

Australian revenue growth, derived (%)

—-49.530.4-29.5

Share Price History

DatePrice (AUD)ContextSource

7 Nov 2018

0.037

Name change to Hydrix

InvestSMART

Apr 2022

~0.10

Placement

MarketIndex

Sep 2022

~0.06

Rights issue

MarketIndex

Dec 2024

~0.012

Director remuneration shares

MarketIndex

28 Oct 2025

0.015

Q1 FY2026 4C

InvestSMART

30 Jan 2026

0.017

Q2 FY2026 4C

InvestSMART

27 Feb 2026

0.016

Half-year update

InvestSMART

18 May 2026

0.013

Entitlement offer announced (offer price 0.005)

InvestSMART

19 Aug 2026

0.003

Post-raise

InvestSMART

Aug–Oct 2026

0.003–0.004

Latest observed

InvestSMART; StockLight

Valuation Multiple Details

Valuation multipleValueComment

Market capitalisation

~A$4–5m (aggregators)

May understate post-conversion share count

EV/Sales (derived, FY2026)

~0.9x–1.0x

EV ≈ ~A$5m market cap + A$7.25m debt − A$2.96m cash ≈ ~A$9.3m pre-conversion; post-conversion EV broadly similar as debt converts to equity

P/S

~0.4x–0.5x

TipRanks shows 0.43x (2025)

Analyst Conclusions

Management guidance. No numerical revenue or earnings guidance. Management states FY2027 should become a period of meaningful value creation as engineering services growth combines with Defence and medical technology commercialisation; it cites A$11.7m FY2026 contract sales, ~A$4.0m of sales since year end, more than 15 active programs with estimated future value above A$37m, new client projects replacing SynCardia from the September 2026 quarter, and SynCardia's possible restart once funded. Consensus: none available.

Bull case

  1. Order intake leads revenue. FY2026 signed contract value rose 18% to A$11.7m with ~A$4.0m added in July–August 2026; if delivered on schedule, FY2027 revenue could exceed the FY2024–FY2026 range of A$9.7–10.6m, and at ~89% employee-cost intensity, incremental utilisation flows strongly to EBITDA.

  2. Balance-sheet reset. Conversion of A$3.9–5.1m of 8–12% director debt removes most of the ~A$1.2m annual finance cost and the current-liability overhang, with A$2.96m cash at 30 June 2026 providing runway that Hydrix lacked in 2025.

  3. Defence optionality at a tiny valuation. With A$2.9m of defence contract sales already and exposure to counter-UAS and quantum navigation, a single successful IP acquisition or licence in a high-priority sovereign domain could re-rate a company valued at roughly 1x EV/sales.

Bear case

  1. Structural unprofitability. The adjusted loss widened to A$3.96m in FY2026 despite two years of cost-cutting; revenue has declined three years running, and the business has never shown sustained group profitability.

  2. Fragile client base. One client's funding pause (SynCardia) produced a A$1.63m Q4 cash outflow; with most clients venture-funded start-ups, similar shocks are likely to recur.

  3. Dilution and capital dependence. The 6-for-1 issue at A$0.005, conversions and ~1 billion-plus options create heavy overhang; the defence acquisition strategy will probably require further equity at depressed prices, and negative equity persists even after conversion.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict.

Hydrix Limited is best understood as two businesses sharing one fragile balance sheet. The first is a genuinely capable, if small, safety-critical engineering consultancy whose credentials in total artificial hearts, LVADs and surgical robotics have won it repeat international work: 73% of FY2026 revenue came from overseas, and contract signings rose 18% to A$11.7m. The second is a listed shell carrying A$116 million of accumulated losses, negative equity of A$8.2 million and a history of option-value ventures — the Guardian distribution rights, the Avertix stake, and now the Gyder mark-down — that have destroyed rather than created value. FY2026 crystallised both: management secured marquee contracts and recapitalised the company, yet revenue fell for a third successive year, the adjusted loss widened, and a single client's funding pause produced the worst quarterly cash burn in two years.

The 2026 recapitalisation materially improves near-term survival odds. Converting most of the directors' 8–12% loans into equity at A$0.005 and holding A$2.96 million of cash at year end gives Hydrix more room than at any point since FY2023. However, the cost is extreme dilution, a large option overhang to 2029, and a capital structure in which further raises are likely if the defence acquisition strategy is pursued in earnest.

The investment case therefore rests on execution evidence that does not yet exist: quarterly revenue recovering above A$2.5–3.0 million as new programs replace SynCardia, operating cash flow returning to breakeven, and a first credible Hydrix Defence IP transaction that does not require ruinous dilution. Until those markers appear, Hydrix should be treated as a highly speculative, binary micro-cap — a call option on Australian sovereign-defence demand and cardiovascular engineering niche demand, underwritten largely by its own directors. Monitoring the October 2026 audited accounts and the next two quarterly cash flow reports is essential before forming any higher-conviction view.


Principal sources

  • Hydrix Limited, Appendix 4E Preliminary Final Report, year ended 30 June 2026 (unaudited), 28 Aug 2026

  • Hydrix Limited, Executive Chairman's Letter, 28 Aug 2026

  • Hydrix Limited, Appendix 4E Preliminary Final Report FY2025, 29 Aug 2025; FY2024 Preliminary Final Report & Market Update, 30 Aug 2024; FY2023 results announcement, 29 Aug 2023; Appendix 4E FY2021 and FY2019

  • Hydrix Limited, Appendix 4D half-year reports (Feb 2023, Feb 2024, Feb 2025, Feb 2026)

  • Hydrix Limited, Appendix 4C quarterly reports (Jan 2025, Apr 2025, Jul 2025, Oct 2025, Jan/Feb 2026, Jul 2026)

  • Hydrix Limited, Prospectus — Entitlement Offer (18 May 2026) and related announcements (20 May, 25 May, 10 Jun, 16 Jun, 18 Jun 2026)

  • Hydrix Limited, Annual Report FY2025 (Grant Thornton auditor; Company Secretary details)

  • Biotech Daily (17 Jul 2020; 15 Feb 2023); FNArena "Dr Boreham's Crucible: Hydrix"

  • Aggregators (flagged where used): TipRanks, Stoxray, Simply Wall St (7 Oct 2024 and management page), MarketIndex, InvestSMART, Morningstar, MarketScreener, Business News

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackgroundRemuneration (latest available)Holding (pre-2026 raise)Source

Gavin Coote

Executive Chairman, Executive Director (acts as de facto CEO; no separate CEO)

Board since Jan 2017 (~9.75 years)

25+ years in corporate/financial strategy and private equity: ~5 years PwC (Australia, USA); ~10 years technology M&A, corporate development and venture investing in the USA; ~15 years Australian private equity (healthcare, construction materials, leisure, sports/entertainment)

~A$358.6k total (aggregator, latest annual)

10.68m shares (~3.9%) indirect via Beachridge Advisory Services Pty Ltd, at 30 Jun 2025

MarketIndex; Simply Wall St

Paul Wright

Independent Non-Executive Director

Since Aug 2018 (~8 years)

Former CEO/MD Universal Biosensors (2011–2016), CEO Invetech (1999–2007), CEO Vision BioSystems Europe (2007–2008); 8+ years at Bain & Company; TNT Logistics corporate development; former NED Memphasys (2020–Sep 2025); Cambridge-educated; FAICD

~A$58k

6.67m shares (~2.4%) + 100k convertible notes, at 30 Jun 2025

MarketScreener; MarketIndex; Simply Wall St

Paul Lewis

Non-Executive Director

Aggregators conflict: ~4.4 years (Simply Wall St) vs appointment noted 31 Jul 2024 (Business News)

—

~A$48k

~7.5% (aggregator)

Simply Wall St; Business News

—

Non-Executive Director

~9 years (aggregator)

—

~A$58k

~11.3% (aggregator)

Simply Wall St

Alyn Tai

Company Secretary

Since Jun 2016

LLB (Hons)

——

Annual report FY2025

Alan Morris

Marketing Director (investor/media contact)

————

Chairman's Letter FY2026

—

Executive

~4.2 years (aggregator)

—

~A$290.9k (aggregator)

—

Simply Wall St

“—” = not publicly disclosed.

Governance Overview

AttributeAssessment

Board size

4 directors (aggregator, early 2026)

Independence

Minority-to-half independent: Paul Wright is described as independent; the Executive Chairman is not; the two other NEDs hold significant stakes (~7.5% and ~11.3%) and directors are also the company's principal lenders, which compromises independence in substance

Chair/CEO separation

Not separated — Executive Chairman model with no CEO; a recognised departure from ASX Corporate Governance Council Recommendation 2.5

Related-party financing

Material: A$5.9m of loans and convertible notes owed to directors at 30 Jun 2026; unsecured related-party loans at 8–12% interest (4C Dec 2025); directors and noteholders committed to convert most of this into equity at A$0.005

Average tenure

Board ~8.3 years (Simply Wall St)

Competitive Landscape

Key Competitors

CompetitorHQPositioning vs Hydrix

Planet Innovation

Melbourne, Australia

Larger Melbourne-based medtech product development and commercialisation group; direct local competitor for talent and clients

Invetech

Melbourne, Australia

Long-established design/engineering and automation firm (Paul Wright is a former CEO); overlaps in medical device and diagnostics development

Cambridge Consultants (Capgemini)

Cambridge, UK

Global-scale deep-tech consultancy; competes for European/US medtech programs with far greater resources

TTP (The Technology Partnership)

Cambridge, UK

Independent technology development firm with strong medtech and drug delivery practice

Science Group plc (incl. Sagentia)

UK (LSE-listed)

Listed science and technology consultancy; broader advisory and product development

StarFish Medical

Victoria, Canada

Medical device design and contract manufacturing; competes for North American start-up programs

Battelle

Columbus, USA

Large non-profit R&D; medical device development for large programs

Ximedica / other US OPD firms

USA

US medtech design-and-development houses competing for venture-funded clients

In-house engineering at client companies

—

The primary substitute as start-ups mature

Key Competitors — DroneShield

CompetitorPositioning

DroneShield (ASX: DRO)

Australian counter-UAS product leader; potential partner/competitor in counter-drone subsystems

Electro Optic Systems (ASX: EOS)

Australian defence technology (remote weapon systems, counter-drone, space); larger-scale sovereign supplier

Nova Systems; other Australian defence engineering SMEs

Engineering services to Defence and primes

Defence primes' in-house engineering (BAE Systems Australia, Thales Australia, etc.)

Primes may subcontract or compete

Key Competitors (2)

CompetitorPositioning

Device-manufacturer remote monitoring platforms (Medtronic, Boston Scientific, Abbott, Biotronik)

Proprietary per-brand monitoring systems; Implicity's pitch is a vendor-agnostic aggregator

Other vendor-agnostic platforms (e.g., PaceMate)

Direct functional competitors in aggregated cardiac device data management

Peer Comparison FY2026

MetricHydrix (FY2026)Cambridge Consultants

Revenue

A$9.74m

Not separately disclosed by Capgemini

Revenue growth

−3.5%—

Net margin

−69.0% (statutory); −40.7% adjusted (derived)

—

“—” = not publicly disclosed.

Company Snapshot

50

Employees

1993

Founded

Victoria, Australia

Headquarters

SWOT Analysis

Strengths

  • Niche leadership credentials in Class III cardiovascular implantables: FY2024: 42% of revenue from cardiovascular clients incl. TAH and LVAD programs; FY2026 SynCardia Emperor TAH contract (A$2.5m)
  • International client base: 73% of FY2026 revenue from outside Australia (63% in FY2025)
  • Improving order intake: FY2026 signed contract value A$11.7m (+18%); ~A$4.0m signed since 30 Jun 2026
  • Proprietary hardware asset: Five LUDO heart controller units sold in FY2024
  • Demonstrated cost discipline: Operating cash burn cut from ~A$6.6m (FY2022) to A$0.53m (FY2025)
  • Committed insider support: Directors provided A$5.9m of loans/notes and committed to convert a majority to equity at A$0.005
  • Product success of clients validates engineering: Gyder Hip System (Hydrix-developed) achieved FDA 510(k) clearance in Feb 2025

Weaknesses

  • Persistent losses: Net losses every year reviewed; FY2026 statutory loss A$6.72m; accumulated losses A$115.9m
  • Negative equity: Total equity −A$8.15m at 30 Jun 2026
  • Going-concern uncertainty: Company expects the FY2026 audit opinion to include a going-concern Emphasis of Matter, as in prior years
  • Revenue stagnation: Revenue fell three consecutive years (A$13.2m FY2023 → A$9.74m FY2026)
  • Cost structure: Employee costs ~89% of revenue (FY2026)
  • Governance concentration: Executive Chairman with no CEO; directors are principal lenders
  • Disclosure errors: Amended Dec 2025 4C corrected receipts by A$1.0m

Opportunities

  • Sovereign defence spending: A$2.9m defence contract sales in FY2026; Hydrix Defence formed to own IP
  • Counter-UAS and GPS-denied navigation: NIOA A$1.2m counter-UAS subsystem; Phasor quantum navigation
  • Surgical robotics growth: Remedy Robotics A$3.4m; Quantanosis stroke robotics
  • Recurring software revenue: Implicity pipeline >A$1.5m potential ARR (H1 FY2026)
  • Ventures liquidity events: Gyder US commercialisation commenced 2026
  • Reduced finance burden: Debt conversion could cut borrowings to ~A$2.2m pro forma (from A$7.25m), reducing ~A$1.2m annual finance costs

Threats

  • Client funding volatility: SynCardia Emperor paused Q4 FY2026; Q4 operating outflow A$1.63m
  • Dilution: 6-for-1 issue at A$0.005 plus conversions; 1:1 options exercisable at A$0.01 to 2029
  • Ventures valuation risk: Portfolio NTA fell ~A$2.8m to A$0.4m in FY2026
  • Medical commercial failure precedent: Guardian TGA application withdrawn (2023); rights impaired to nil (FY2024)
  • Larger competitors in defence: Established Australian defence tech SMEs and primes
  • Execution risk of acquisitions: Hydrix Defence has no announced target and limited capital (A$2.96m cash at 30 Jun 2026)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Apr 2025Q3 FY2025 4C: Services revenue A$2.1m; group cash operating loss A$0.75m (vs A$1.35m pcp); Gyder FDA 510(k) triggers A$0.36m Ventures uplift; caution in global markets delaying project starts 4C, 30 Apr 2025Cost-out working; macro headwinds
31 Jul 2025Q4 FY2025 4C: revenue A$2.4m (+10% QoQ); 18 contract wins worth A$3.5m; 20 active paying clients; ~A$40m pipeline; cash A$0.3m plus A$2.0m letter of comfort (A$0.75m drawn); emerging defence clients 4C, 31 Jul 2025Liquidity tight; sales improving
29 Aug 2025FY2025 Preliminary Final Report: revenue A$10.1m (−4.9%); loss sharply reduced; 63% revenue international Appendix 4E FY2025Turnaround narrative
10 Oct 2025FY2025 audited Annual Report lodged (Grant Thornton) Annual reportCompliance
28 Oct 2025Q1 FY2026 4C: second consecutive quarter of Services revenue growth; group operating loss A$0.57m (25% better than June quarter); cash A$308k; A$2.5m letters of comfort; financing facilities A$5.56m 4C, 28 Oct 2025Momentum but minimal cash
Late 2025Governance
Dec 2025 / Jan 2026A$2.5m multi-year SynCardia Emperor TAH contract 4C, 30 Jan 2026Marquee cardiovascular win
30 Jan 2026Q2 FY2026 4C: revenue A$2.3m; operating cash inflow A$49k; cash A$582k; facilities A$6.959m (A$6.786m drawn) 4C, 30 Jan 2026Facilities nearly exhausted
2 Feb 2026Amended 4C correcting customer receipts from A$3.386m to A$2.386m (typographical error)Disclosure-control weakness
27 Feb 2026Half-year report and trading update: A$3.7m quarter-to-date sales; ~A$40m future revenue potential over 2–3 years; cash A$0.6m with A$2.2m letter of comfort; Medical pipeline >A$1.5m ARR Appendix 4D; trading updateGrowth outlook vs liquidity strain
18 May 2026A$8.18m 6-for-1 entitlement offer at A$0.005 with 1:1 options (A$0.01, exp. 30 Jun 2029); prospectus also covers note and director-loan conversions Prospectus; ASXHighly dilutive recapitalisation; share price fell from ~A$0.013
20 May 2026Institutional component raises A$3.89m; "Hydrix positioned for Defence tech expansion" ASX announcementsFirst-stage funding secured
25 May 2026Hydrix Defence Pty Ltd established; retail offer opens ASX announcementsStrategic pivot formalised
26 May 2026Top 20 holders and distribution of new options; quotation of new shares ASXCapital structure change
29 May 2026Hydrix Defence Strategic Growth Plan investor presentation ASXStrategy articulation
4 Jun 2026Phasor Innovation contracts Hydrix for quantum navigation technology ASXDefence credibility
5 Jun 2026Retail entitlement offer closes Prospectus—
9 Jun 2026HYDOC options class suspended from quotation (pending completion of issue) ASXAdministrative
10 Jun 2026Retail offer results; A$4m minimum condition for debt conversion satisfied ASXConversion unlocked
16 Jun 2026Retail shortfall bookbuild completes; A$5.22m raised in total (of A$8.18m) ASX~64% take-up
17 Jun 2026European defence market engagement announced ASXInternational defence BD
18–19 Jun 2026New shares and HYDOC options issued; trading commences 19 June ASX—
22 Jun 2026Further quotation of securities; cessation of securities notice ASXCapital structure
Q4 FY2026SynCardia Emperor program paused due to client funding; delayed receivable Appendix 4E FY2026Revenue and cash hit
Jun–Jul 2026Largest FY2026 single win
30 Jul 2026Q4 FY2026 4C: revenue A$2.2m; operating outflow A$1.63m; A$5.207m equity inflow; A$6.5m new contracts 4C, 30 Jul 2026Cash burn spike, liquidity restored
19 Aug 2026Executive Chair interview on ausbiz ASXInvestor engagement
28 Aug 2026FY2026 Appendix 4E and Chairman's Letter: revenue A$9.74m; statutory loss A$6.72m; adjusted loss A$3.96m; cash A$2.96m; A$11.7m FY2026 contract sales; ~A$4.0m sales since year end; going-concern EoM expected Appendix 4E; Chairman's LetterInflection claimed; losses persist
4 Sep 2026Retail Shortfall Facility closes (determines final debt-conversion quantum) Appendix 4E FY2026Final capital structure
~20 Oct 2026 (scheduled)Audited FY2026 Annual Report due InvestSMART calendarWatch audit opinion

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from contracts with customers fell from AUD 10.3 Mn in FY2022 to AUD 9.7 Mn in FY2026.
Hydrix Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from contracts with customers10.313.210.610.19.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.